
PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

To:
G.D. SEARLE & CO.
Corporate Patent Department
Attn. WILLIAMS, R.
P.O.Box 5110
Chicago, Illinois 60680-5110
UNITED STATES OF AMERICA



	P.O.Box 5110 Chicago, Illinois 60680-5110 UNITED STATES OF AMERICA	(PCT Rule 44.1)
		Date of mailing (day/month/year) 29/01/1999
_	Applicant's or agent's file reference 3122/PCT	FOR FURTHER ACTION See paragraphs 1 and 4 below
_	International application No. PCT/US 98/19366	International filing date (day/month/year) 17/09/1998
	Applicant MONSANTO COMPANY et al.	Pulling 3/19/20
	1. X The applicant is hereby notified that the International Search Filling of amendments and statement under Article 19 The applicant is entitled, if he so wishes, toamend the claim When? The time limit for filing such amendments is norma International Search Report; however, for more de Where? Directly to the International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Fascimile No.: (41-22) 740.14.35 For more detailed Instructions, see the notes on the account of the applicant is hereby notified that no International Search Article 17(2)(a) to that effect is transmitted herewith. 3. With regard to the protest against payment of (an) addition the protest together with the decision thereon has been applicants's request to forward the texts of both the protest; the applicant of the protest of the protest; the applicant of the protest of the	is of the International Application (see Rule 46): Ally 2 months from the date of transmittal of the stails, see the notes on the accompanying sheet. In Report will be established and that the declaration under small fee(s) under Rule 40.2, the applicant is notified that: In transmitted to the International Bureau together with the otest and the decision thereon to the designated Offices.
	Further action(s): The applicant is reminded of the following:	
	The state of the s	

Shortly after 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

Within 19 months from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within 20 months from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the International Searching Authority

European Patent Office, P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Authorized officer

Barbara Klaver

Fax: (+31-70) 340-3016

Form PCT/ISA/220 (January 1994)

NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international polication. Furthermore, it should be emphasized that provisional protection is available in some States only.

What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been its filed, see below.

How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

- [Where originally there were 48 claims and after amendment of some claims there are 51]:
 "Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
- [Where originally there were 15 claims and after amendment of all claims there are 11]:
 "Claims 1 to 15 replaced by amended claims 1 to 11."
- [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims):
 "Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or
 "Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
- 4. [Where various kinds of amendments are made]: "Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claims 14, claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

"Statement under article 19(1)" (Rule 46:4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

it must be in the language in which the international appplication is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the same time of filing the amendments with the International Bureau, also file a copy of such amendments with the International Preliminary Examining Authority (see Rule 62.2(a), first sentence).

Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER see Notification of (Form PCT/ISA/22	Transmittal of International Search Report 20) as well as, where applicable, item 5 below.
3122/PCT International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)
		19/09/1997
PCT/US 98/19366	17/09/1998	13/03/133
Applicant		
MONSANTO COMPANY et al.		
This International Search Report has been according to Article 18. A copy is being to	en prepared by this International Searching Auth ransmitted to the International Bureau.	nority and is transmitted to the applicant
This International Search Report consist	s of a total of sheets.	
X It is also accompanied by a co	by of each priorant document cited in this report	
	habta/coa Boy I)	
1. Certain claims were found u	usestettante (seerpov.t).	ĺ
2. Unity of invention is lacking	(see Box II).	
2		· · · · · · · · · · · · · · · · · · ·
3. The international application c	ontains disclosure of a nucleotide and/or amIn id out on the basis of the sequence listing	o acld sequence listing and the
T T file	ed with the international application.	
fu	mished by the applicant separately from the inte	emational application,
	but not accompanied by a statement to the matter going beyond the disclosure in the	he effect that it did not include
·		:
_ τ	anscribed by this Authority	
4. With regard to the title, th	e text is approved as submitted by the applican	ıt.
4. With regard to the title, X	e text has been established by this Authority to	read as follows:
DNA VACCINATION AGAI	NST CHOLESTEROL ESTER TRANSF	FER PROTEIN IN THE TREATMENT
OF ATHEROSCLEROSIS	M31 011022012.102 2312	
0		
5. With regard to the abstract,		
1 🛎	ne text is approved as submitted by the applican	29 2/b) by this Authority as it annears in
1	ne text has been established, according to Rule lox III. The applicant may, within one month from	mine date of maining of this intomation.
Š	Search Report, submit comments to this Authori	ty.
6. The figure of the drawings to be p	ublished with the abstract is:	
Figure No. —	is suggested by the applicant.	None of the figures.
	pecause the applicant failed to suggest a figure	
] .	pecause this figure better characterizes the inve	ntion.

Form PCT/ISA/210 (first sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/19366

Box I	Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)
This Inte	ernational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: Remark: Although claims 1-16 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
з. 🗌	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of Invention is lacking (Continuation of item 2 of first sheet)
This Inte	rmational Searching Authority found multiple inventions in this international application, as follows:
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark	on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No PCT/US 98/19366

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C12N15/12 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

 $\label{localization} \begin{array}{ll} \mbox{Minimum documentation searched (classification system followed by classification symbols)} \\ \mbox{IPC 6} & \mbox{A61K} \end{array}$

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
χ	THOMAS L J ET AL: "A PLASMID-BASED VACCINE TO ELICIT AUTOANTIBODIES TO CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) FOR THE PREVENTION/TREATMENT OF	1-12, 15-21
	ATHEROSCLEROSIS" JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 99, no. 1, PART 02, January 1997, page S187 XP002041706 see abstract 754	
X	O'BRIEN C: "Vaccine for atherosclerosis 'news!." MOLECULAR MEDICINE TODAY, (1997 JUN) 3 (6) 231. JOURNAL CODE: CMK. ISSN: 1357-4310., XP002090145 ENGLAND: United Kingdom see the whole document	1÷12, 15~21
	 -/	

X Further documents are listed in the continuation of box C.	χ Patent family members are listed in annex.
Special categories of cited documents: A document defining the general state of the art which is not considered to be of particular relevance E earlier document but published on or after the international filling date L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) O document referring to an oral disclosure, use, exhibition or other means P document published prior to the international filing date but later than the priority date claimed	T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "8" document member of the same patent family
Date of the actual completion of the international search	Date of mailing of the international search report
15 January 1999	29/01/1999
Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl. Fax: (+31-70) 340-3016	Sitch, W

2

INTERNATIONAL SEARCH REPORT

International Application No PCT/US 98/19366

C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to daim No.
X	WO 96 34888 A (T CELL SCIENCES INC; RITTERSHAUS CHARLES W (US); THOMAS LAWRENCE J) 7 November 1996 see page 5, line 28 - page 8, line 4	1-12, 15-21
A	SCHÖDEL ET AL: "THE POSITION OF HETEROLOGOUS EPITOPES INSERTED IN HEPATITIS B VIRUS CORE PARTICLES DETERMINES THEIR IMMUNOGENICITY" JOURNAL OF VIROLOGY, vol. 66, 1992, pages 106-114, XP002090146 cited in the application see the whole document	13,14
A	MELCHIOR ET AL: "CHOLESTERYL ESTER TRANSFER PROTEIN'S ROLE IN HIGH-DENSITY LIPOPROTEIN METABOLISM" TRENDS IN CARDIOVASCULAR MEDICINE, vol. 5, 1995, pages 83-87, XP002090147 cited in the application see page 83 see abstract	
A .	EVANS ET AL: "INHBITION OF CHOLESTERYL ESTER TRANSFER PROTEIN_IN NORMOCHOLESTEROLEMIC AND HYPERCHOLESTEROLEMIC HAMSTERS: EFFECTS ON HDL SUBSPECIES, QUANTITY, AND APOLIPOPROTEIN DISTRIBUTION" JOURNAL OF LIPID RESEARCH, 1994, pages 1634-1645, XP002090148 35 cited in the application see page 1634 see abstract	
A .	GAYNOR ET AL: "INHIBITION OF CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY IN HAMSTERS ALTERS HDL LIPID COMPOSITION" ATHEROSCLEROSIS, vol. 110, 1994, pages 101-109, XP002090149 cited in the application see page 101 see abstract	

2

		PCT/US 98	3/19366
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.
А	SUGANO ET AL: "CHANGES IN PLASMA LIPOPROTEIN CHOLESTEROL LEVELS BY ANTISENSE OLIGODEOXYNUCLEOTIDES AGAINST CHOLESTERYL ESTER TRANSFER PROTEIN IN CHOLESTEROL-FED RABBITS" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, 1996, pages 19080-19083, XP002090150 cited in the application see page 19080 see abstract		
A	MELCHIOR ET AL: "EVIDENCE THAT CYNOMOLGUS MONKEY CHOLESTERYL ESTER TRANSFER PROTEIN HAS TWO NEUTRAL LIPID BINDING SITES" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, 1995, pages 21068-21074, XP002090151 cited in the application see page 21068 see abstract		
P,X	WO 97 41227 A (T CELL SCIENCES INC ; THOMAS LAWRENCE J (US)) 6 November 1997 see page 6, line 17 - page 8, line 30		1-12, 15-21
	•		
	·		

Information on patent family memb			PCT/US 98/19366		
Patent document cited in search repo		Publication date		ratent family member(s)	Publication date
WO 9634888	A	07-11-1996	AU CA EP	5636096 A 2219795 A 0827509 A	21-11-1996 07-11-1996 11-03-1998
WO 9741227	A	06-11-1997	AU	2994697 A	19-11-1997

International Application No

INTERNATIONAL SEARCH REPORT